CAR T-cell therapy for CD19-positive leukemias and lymphomas
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of leukemia or lymphoma called CLL, SLL, or B-cell ALL that has the CD19 protein.
- If you have CLL/SLL, you need to have tried at least 2 treatments, including a BTK inhibitor (like ibrutinib).
- Your cancer must be measurable on scans or found in blood or bone marrow.
- You need to be 18 or older, in good overall health, and have normal organ function (heart, kidneys, liver, blood counts).
- You cannot have had prior CAR T-cell therapy or certain other treatments like checkpoint inhibitors within 180 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
This trial tests an immunotherapy called CAR T cells for leukemia that has come back or is hard to treat. It aims to use your own immune cells to fight the cancer.
This trial tests whether a new immune therapy (CAR-T cells) can treat certain types of blood cancers that have come back or not responded to standard treatments. It aims to help people with aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) that hasn't been controlled by other therapies.
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
This Phase 1 study tests a personalized form of immune therapy called CAR T cells that are designed to recognize CD19, a marker on certain B-cell cancers. It may help people with difficult-to-treat (recurrent or relapsed) B-cell lymphoma or leukemia (ALL/CLL).
Hear when a new Leukemia, Lymphocytic, Chronic, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.